**Appendix Table E82. Results from studies assessing the ability of TEG to predict death in patients with ischemic heart disease**

| **Author,year****UID****Country****Study name** | **Treatment** | **Phenotypic Test Used [index test]** | **Clinical Outcome** | **Outcome Definition** | **Timing of measurement** | **Index test result: category (e.g., HPR+) – ONE ROW PER PHENOTYPE GROUP** | **Outcome status (e.g., bleeding or no bleeding)** | **No. with outcome status within phenotype group** | **Comparative metric (OR, RR, HR)** | **95% CI** | **P (between which groups?)****[statistical test]** | **Adjusted?****[YES/NO/NR]****If YES, for what factors?** | **Procedures for multiple comparisons [YES, NO, NR]** | **Comments (e.g., additional data in figures)** |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Bliden, 200617291930USANR | clopidogrel75 mg qd | ADP-induced platelet reactivity  | death | death | Day 0-30 | Total n=100 | death | 0/100 | NR | NR | NR | NR | NR | Figure 2 with dotted box plot for association of ADP inducing light transmittance aggregometry |
|  |  |  |  |  | Day 31-365 | Total n=100 | death | 0/100 |  |  |  |  |  |  |
|  | clopidogrel75 mg qd | ADP-induced platelet reactivity  | death) | death | Day 0-30 | HPR n=22 | death | 0/22 | OR=3.5 (calculated) | NR | p=0.54 HPR vs NPRFisher’s exact test | NR | NR |  |
|  |  |  |  |  | Day 0-30 | NPRN=78 | death | 0/78 |  |  |  |  |  |  |
|  | clopidogrel75 mg qd | ADP-induced platelet reactivity  | death | death | Day 31-365 | HPR n=22 | death | 0/22 | OR=3.5 (calculated) | NR | p=0.54 HPR vs NPRFisher’s exact test | NR | NR |  |
|  |  |  |  |  | Day 31-365 | NPRN=78 | death | 0/78 |  |  |  |  |  |  |
| Tang, 201222490487ChinaNR | 100mg aspirin and 75 mg clopidogrel (con) | ADP-induced platelet reactivity | cardiovascular death | cardiovascular death | 6 months | control group | cardiovascular death | 0/30=0 | OR=3.10(calculated) | 0.12-79.23 | **>0.05** | **NR** | **NR** | **from table 4** |
|  | 100 mg aspirin and 75 mg clopidogrel (R+R) |  | cardiovascular death | cardiovascular death | 6 months | resistance plus routine | cardiovascular death | 1/30=3% |  |  |  |  |  |  |
|  | 200 mg aspirin and150 mg clopidogrel (R+L) |  | cardiovascular death | cardiovascular death | 6 months | resistance plus loading dose  | cardiovascular death | 0/30=0 |  |  |  |  |  |  |
|  | 100mg aspirin and 75 mg clopidogrel (con) | ADP-induced platelet reactivity | cardiovascular death | cardiovascular death | 12 months | control group | cardiovascular death | 0/30=0 | OR=3.10(calculated) | 0.12-79.23 | **>0.05** | **NR** | **NR** | **from table 5** |
|  | 100mg aspirin and 75 mg clopidogrel (R+R) |  | cardiovascular death | cardiovascular death | 12 months | resistance plus routine | cardiovascular death | 1/30=3% |  |  |  |  |  |  |
|  | 200mg aspirin and150 mg clopidogrel (R+L) |  | cardiovascular death | cardiovascular death | 12 months | resistance plus loading dose  | cardiovascular death | 0/30=0 |  |  |  |  |  |  |